Clemondo Group (CLEM) Q1 2026 earnings summary

Executive summary

• Net sales increased by 5% to 79.1 MSEK compared to Q1 2025, marking the seventh consecutive quarter of growth, mainly driven by Medical Care.

• EBITDA decreased to 5.5 MSEK (from 7.9 MSEK), with margin at 6.8% (down from 10.3%), due to higher costs from strategic investments.

• Net income fell to 1.0 MSEK (from 3.1 MSEK), and EPS was 0.07 SEK (down from 0.23 SEK).

• New CEO Peter Andersson took office on January 1, 2026.

Financial highlights

• Gross margin improved to 41.3% (from 38.5%), with gross profit up by 3.9 MSEK year-over-year.

• Cash flow from operations before working capital changes was 3.8 MSEK (down from 6.8 MSEK); after changes, it was -0.6 MSEK (down from 5.7 MSEK).

• Financial net was -0.6 MSEK (down from 0.3 MSEK).

• Equity at quarter-end was 119.7 MSEK, with a balance sheet total of 224.7 MSEK.

Outlook and guidance

• Management expects continued positive trend, though growth may not be linear.

• Focus remains on long-term growth, especially in Medical Care and expansion into Norway.